Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
04 01 2023
04 01 2023
Historique:
received:
03
10
2022
revised:
12
10
2022
accepted:
27
10
2022
pubmed:
29
10
2022
medline:
6
1
2023
entrez:
28
10
2022
Statut:
ppublish
Résumé
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs, patient-derived xenograft models from human brain metastases and phase 0 and window-of-opportunity trials are of utmost importance. See related article by Kabraji et al., p. 174.
Identifiants
pubmed: 36305867
pii: 710102
doi: 10.1158/1078-0432.CCR-22-2853
doi:
Substances chimiques
trastuzumab deruxtecan
5384HK7574
Receptor, ErbB-2
EC 2.7.10.1
Antibodies, Monoclonal, Humanized
0
Trastuzumab
P188ANX8CK
Camptothecin
XT3Z54Z28A
Immunoconjugates
0
Types de publication
Editorial
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
8-10Commentaires et corrections
Type : CommentIn
Type : CommentOn
Informations de copyright
©2022 American Association for Cancer Research.